Quick Answer
Adicet Bio, Inc. reported Cash and Equivalents of $38.92 million for fiscal year 2025.
Adicet Bio, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $38.92M | -31.1% |
| 2024 | $56.49M | -64.6% |
| 2023 | $159.71M | -38.0% |
| 2022 | $257.66M | -7.2% |
| 2021 | $277.54M | +229.1% |
| 2020 | $84.33M | +695.0% |
| 2019 | $10.61M | +11.9% |
| 2018 | $9.47M | -82.2% |
| 2017 | $53.35M | — |
| 2016 | $0.00 | — |
| 2016 | $0.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $29.10M | -72.4% | -16.2% |
| June 30, 2025 | $34.72M | -84.5% | +23.4% |
| March 31, 2025 | $28.13M | -82.4% | -50.2% |
| December 31, 2024 | $56.49M | -64.6% | -46.4% |
| September 30, 2024 | $105.48M | -42.4% | -52.9% |
| June 30, 2024 | $224.07M | +9.1% | +40.3% |
| March 31, 2024 | $159.71M | -31.1% | +0.0% |
| December 31, 2023 | $159.71M | -38.0% | -12.8% |
- Adicet Bio, Inc. showed a decrease of -31.1% in Cash and Equivalents compared to the prior fiscal year.
- The most recent figure is from Adicet Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: